申请人:ONO PHARMACEUTICAL CO., LTD.
公开号:EP2371811A2
公开(公告)日:2011-10-05
A compound represented by the formula (IC-2), a salt thereof, an N-oxide form thereof, a solvate thereof, a prodrug thereof, or a number of specific compounds and pharmaceutical compositions comprising these compounds. The compound has the ability to combine with an SIP receptor (especially EDG-1, EDG-6 and/or EDG-8). It is useful for the prevention and/or treatment of rejection reactions to transplantation, graft versus host diseases, autoimmune diseases, allergic diseases, neurodegenerative diseases etc.
由式(IC-2)代表的化合物、其盐、其 N-氧化物形式、其溶液剂、其原药或一些特定化合物以及包含这些化合物的药物组合物。该化合物具有与 SIP 受体(尤其是 EDG-1、EDG-6 和/或 EDG-8)结合的能力。它可用于预防和/或治疗移植排斥反应、移植物抗宿主疾病、自身免疫性疾病、过敏性疾病、神经退行性疾病等。